Oral HMAs May Provide Safer and More Effective Treatment Options for MDS

Guillermo Garcia-Manero, MD, spotlights the evolution of oral azacitidine- and decitabine-based regimens for MDS.

Related Keywords

Houston ,Texas ,United States ,Guillermo Garcia Manero ,Translational Research ,International Prognostic Scoring System ,Division Of Cancer Medicine ,University Of Texas Md Anderson Cancer Center ,Department Of Leukemia ,Faculty Senate ,Myelodysplastic Syndromes ,Cancer Medicine ,Cancer Center ,Revised International Prognostic Scoring System ,Myeloproliferative Neoplasms ,Bmpn ,D ,Oral Regimens ,Azacitidine ,Decitabine ,Astx030 ,Inqovi ,Decitabine Plus Cedazuridine ,Azacitidine Plus Cedazuridine ,Hypomethylating Agents ,Phma ,